European Commission Approved New Triple-Combo Asthma Inhaler
Patients 12 and older with uncontrolled asthma may have a new maintenance option for their daily care.
Updated on Sept. 23, 2026 in Asthma
Live Poll
Do you believe new medical treatment options are effectively improving health outcomes for chronic illness patients?
The European Commission has approved the triple-combination inhaler Trixeo as a maintenance treatment for patients aged 12 and older whose asthma remains uncontrolled by dual therapies. This new option serves nearly 43 million people living with the condition across Europe.
Why it matters
This approval provides a new treatment pathway for patients who do not find symptom relief with standard two-drug inhalers. It marks an expansion in the approved use for the medication, which is already used for chronic obstructive pulmonary disease.
Clinical findings from the KALOS and LOGOS trials involving approximately 4,300 patients supported the regulatory approval. The study design assessed the therapy for patients who failed to reach control on dual-drug regimens.
The players
European Commission
The executive branch of the European Union that oversees regulatory approvals for pharmaceutical products.
AstraZeneca
A global biopharmaceutical company that develops and manufactures respiratory, oncology, and cardiovascular therapies.
The details
Trixeo functions by combining three active pharmaceutical ingredients into a single device to address asthma management. This triple-action approach works by opening constricted airways and reducing inflammation, providing a more intensive treatment than traditional two-drug inhalers. It is already established in clinical practice, having been prescribed to over 6.8 million COPD patients in 2025.
Timeline
2025: Trixeo was prescribed to over 6.8 million COPD patients.
September 2026: The European Commission approved Trixeo for asthma treatment.
Health Landscape
The approval of Trixeo represents an expansion of existing maintenance treatment options for individuals with chronic respiratory conditions. It follows the established clinical history of the medication, which has already been widely utilized for COPD.
Patients who still experience symptoms on current dual-inhaler regimens should speak with their physician to determine if this new maintenance therapy is appropriate for their care plan. This discussion should focus on individual treatment history and the specific goals for long-term airway control.
The takeaway
Triple-combination therapies offer a significant step up for patients whose symptoms are not controlled by standard dual treatments. If you are currently struggling with asthma symptoms, ask your healthcare provider about whether a triple-therapy approach is a suitable next step for your health.
Further reading
For more on managing long-term lung health, explore our Asthma section.
Live Poll
Do you believe new medical treatment options are effectively improving health outcomes for chronic illness patients?
